Австралія - англійська - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - exemestane, quantity: 25 mg - tablet, film coated - excipient ingredients: crospovidone; sodium starch glycollate type a; hypromellose; magnesium stearate; mannitol; microcrystalline cellulose; colloidal anhydrous silica; polysorbate 80; titanium dioxide; macrogol 400 - exemestane is indicated for the sequential adjuvant treatment of estrogen receptor-positive early breast cancer in post-menopausal women who have received prior adjuvant tamoxifen therapy. . exemestane is indicated for the treatment of estrogen receptor-positive advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-estrogen therapy.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - exemestane -

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - exemestane, quantity: 25 mg - tablet, film coated - excipient ingredients: mannitol; polysorbate 80; microcrystalline cellulose; hypromellose; macrogol 400; colloidal anhydrous silica; titanium dioxide; magnesium stearate; sodium starch glycollate type a; crospovidone - exemestane sandoz is indicated for the sequential adjuvant treatment of oestrogen receptor-positive early breast cancer in post-menopausal women who have received prior adjuvant tamoxifen therapy.,exemestane sandoz is indicated for the treatment of oestrogen receptor-positive advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - exemestane, quantity: 25 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate type a; hypromellose; mannitol; microcrystalline cellulose; magnesium stearate; crospovidone; polysorbate 80; titanium dioxide; macrogol 400 - exemestane is indicated for the sequential adjuvant treatment of oestrogen receptor-positive early breast cancer in post-menopausal women who have received prior adjuvant tamoxifen therapy. . exemestane is indicated for the treatment of oestrogen receptor-positive advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy.

США - англійська - NLM (National Library of Medicine)

greenstone llc - exemestane (unii: ny22hmq4bx) (exemestane - unii:ny22hmq4bx) - exemestane 25 mg - exemestane is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane for completion of a total of five consecutive years of adjuvant hormonal therapy [see clinical studies (14.1)]. exemestane is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see clinical studies (14.2)]. exemestane is contraindicated in patients with a known hypersensitivity to the drug or to any of the excipients. risk summary based on findings in animal studies and its mechanism of action, exemestane can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . limited human data from case reports are insufficient to inform a drug-associated risk. in animal reproduction studies, administration of exemestane to pregnant rats and rabbits caused increased incidence of abortions, embryo-fet

Канада - англійська - Health Canada

teva canada limited - exemestane - tablet - 25mg - exemestane 25mg - antineoplastic agents

Канада - англійська - Health Canada

genmed a division of pfizer canada ulc - exemestane - tablet - 25mg - exemestane 25mg - antineoplastic agents

Канада - англійська - Health Canada

generic medical partners inc - exemestane - tablet - 25mg - exemestane 25mg - antineoplastic agents

Канада - англійська - Health Canada

mylan pharmaceuticals ulc - exemestane - tablet - 25mg - exemestane 25mg - antineoplastic agents

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - exemestane 25mg - coated tablet - 25 mg - active: exemestane 25mg excipient: crospovidone hydrated silica hypromellose   macrogol 6000 magnesium carbonate magnesium stearate mannitol methyl hydroxybenzoate polysorbate 80 polyvinyl alcohol powdered cellulose simeticone sodium starch glycolate sucrose   titanium dioxide - · the adjuvant treatment of postmenopausal women with oestrogen receptor positive or receptor unknown early breast cancer after initial adjuvant tamoxifen to reduce the risk of recurrence (distant and loco-regional) and contralateral breast cancer · the treatment of advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy · the third-line hormonal treatment of advanced breast cancer in women with natural or induced postmenopausal status whose disease progressed following treatment with anti-oestrogens and either non-steroidal aromatase inhibitors or progestins.